Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

NCT02414841 is registered in ClinicalTrials.gov with Proteon Therapeutics as lead sponsor.

NCT NCT02414841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02414841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Lead sponsor
Proteon Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2015
Completion date
May 1, 2019
Enrollment
696 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease